1.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7373-A001-401, NCT01011283
|
|
2.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 120
Sponsor: Other
Protocol IDs: TUD-RELAZA-008, 2006-001040-31 (EudraCT Nr.), NCT00422890
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2008-0503, NCT00887068
|
|
5.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: JHOC-J0658, J0658, 7759, NCI-7759, JHOC-NA_00003114, NCT00387465
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NYCC-6898, 6898, NCI-6898, NCT00392353
|
|
7.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2007-0030, NCT00529022
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 and over
Sponsor: Other
Protocol IDs: VAST-B, NCT00748553
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 050938, NCT00766116
|
|
10.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 50 and over
Sponsor: NCI
Protocol IDs: FHCRC-2288.00, FHCRC-2288.00, 8297, IR-6921, NCT00895934
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: SU-04242009-2385, HEMAML0011, NCT00890929, RV-AML-0410, NCT00890929
|
|
12.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000558043, EPROST-20061143, SCCC-2006080, SCCC-EPROST-20061143, WIRB-20070344, PHARMION-SCCC-2006080, NCT00503984
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 11570, NCT00934440
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: 0907010513, NCT01004991
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1905, E1905, NCT00313586
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P050202, NCT00339196
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: NCI
Protocol IDs: MCC-14496, MCC-104331, NCT00387647
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0428, NCT00413478
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AH213/06, NCT00412919
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: GFM aza05, NCT00446303
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-000972-18, SIMIDIS, NCT00495547
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: NCI
Protocol IDs: SWOG-S0703, S0703, NCT00658814
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: TASMC-08-MM-TLV-0069-08-CTIL, NCT00704704
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: MCC-11328, NCT00721214
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: SK0010, NCT00728520
|
